A football manager is warning 'stubborn' men not to ignore symptoms - after growing a beard to hide a 'spot' on his face that turned out to be cancer. Simon Heaton first noticed a pinprick-sized spot ...

As China is intensifying efforts to deepen international collaboration and investment in its high-tech medical sectors, ...

Use of the anti-CD19 CAR T-cell therapy obecabtagene autoleucel (obe-cel; Aucatzyl) resulted in durable remissions among ...

BeiGene ($BGNE) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high ...

CARGO Therapeutics (CRGX) stock receives Outperform rating from William Blair due to potential of its lead candidate firicabtagene autoleucel (firi-cel). Read more here.

For CAR T-cell therapies, there were notable additions for its use after 1 and 2 prior lines of therapy, 1 both category 1 ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These ...

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

LPX-TI641, a therapy to promote immune system balance in MS and other autoimmune diseases, was assessed at varying doses in a ...

These therapies are designed to combat antibody-producing cells, B-cells, that mistakenly trigger immune responses against ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...